Abstract. Delisheng is a widely used antineoplastic agent in China. Although previous studies revealed that Delisheng exhibits numerous pharmacological effects including the inhibition of cancer cell differentiation and enhancement of immune function with the lowest toxicity, the precise anticancer mechanisms of Delisheng in human hepatocellular carcinoma (HCC) cells remains largely unknown. The present study investigated the potential mechanisms underlying the anticancer properties of Delisheng on Hep3B cells. Delisheng demonstrated a strong anti-proliferation effect on Hep3B cells compared with normal liver HL-7702 cells, as detected by MTT assays. In addition, Delisheng arrested the cells in G/G 1 phase. Furthermore, it exhibited a pro-apoptotic effect on Hep3B cells, as detected by flow cytometry. When exposed to Delisheng, Hep3B cells demonstrated decreased vascular endothelial growth factor (VEGF) and osteopontin (OPN) and increased endostatin (ES) protein expressions, as detected using immunocytochemistry staining and western blotting. These data suggest that Delisheng induces antiproliferation and apoptosis of Hep3B cells via modulation of VEGF, OPN and ES protein expression. It is hypothesized that Delisheng may be used as a novel anticancer therapeutic in HCC.
Introduction
Hepatocellular carcinoma (HCC) is an aggressive neoplasm with an increasing incidence, representing the fifth most common cancer globally (1) . It is also the third leading cause of cancer-associated mortality (2) . Surgical resection is the cornerstone of therapeutic strategy in the early stages of HCC. However, numerous patients with HCC with advanced or distant metastatic disease are not candidates for these therapies (3) . HCC is well characterized as demonstrating an inherently chemotherapy-refractory nature, and systemic cytotoxic chemotherapy agents exhibit minimal effectiveness on improving patient survival (4, 5) . Therefore, exploring novel anticancer agents that are more effective for HCC is important. A number of traditional Chinese medicines, with wide use in clinical practice in China, have been the source of novel anticancer drug developments (6) (7) (8) (9) (10) . Delisheng, a Chinese medicinal compound that consists of ginseng, milk vetch root, bufonis secretions and cantharidium (11) , has previously attracted attention (11) , but the potential molecular mechanisms underlying its anticancer effect are unknown.
During carcinogenesis, angiogenesis exhibits a key role in regulating physiological functions (12) . This process is characterized by decreasing levels of antiangiogenic proteins and increasing levels of factors that stimulate vasculogenesis (13) . Despite previous studies demonstrating that vascular endothelial growth factor(VEGF), osteopontin (OPN) and endostatin (ES) are involved in tumor angiogenesis (14, 15) , their association with HCC is poorly understood.
In the present study, human hepatocarcinoma Hep3B cells and normal liver HL-7702 cells were utilized to further study the underlying mechanisms of the anticancer effects of Delisheng. It was demonstrated that Delisheng exhibits anti-proliferative and pro-apoptotic effects on Hep3B cells, and that the angiogenic proteins VEGF, OPN and ES are involved in this process.
Materials and methods
Cell culture. The human hepatocarcinoma Hep3B and normal liver HL-7702 cell lines were purchased from Chinese Academy of Sciences Institute of Life Sciences Cell Resource Center (Shanghai, China). They were grown in RPMI-1640 medium and Dulbecco's modified Eagle's medium (DMEM; GE Healthcare Life Sciences; Hyclone, Logan, UT, USA), respectively. The cell cultures contain 10% fetal bovine serum (GE Healthcare Life Sciences; Hyclone) and 100 U/ml penicillin and streptomycin (Gibco; Thermo Fisher Scientific, Waltham, MA, USA) at 37˚C with 5% CO 2 . Then, cells were harvested in the logarithmic growth phase for subsequent experiments. Cell-cycle analysis. The Hep3Bcells treated with Delisheng (2x10 5 cells/group) were trypsinized, washed twice with cold PBS and harvested by centrifugation at 4,000 x g and 37˚C for 5 min, and then incubated in 100 µg/ml propidium iodide (PI) with RNaseA (5 µg/ml) following fixation with 70% ice-cold ethanol at room temperature (RT) for 30 min. Cellular DNA content was subsequently analyzed by flow cytometry analysis on a BD FACSCalibur system (BD Biosciences, Franklin Lakes, NJ, USA), as previously described (16) .
Delisheng induces antiproliferation and apoptosis effects in Hep3B cells via modulation of angiogenic proteins
Cell apoptosis assay. Hep3B and HL-7702 cells treated with 25, 50 and 100 µl/ml Delisheng were collected and washed twice with cold PBS, and centrifuged at 5,000 x g for 5 min, followed by staining with 5 µl Annexin V-fluorescein isothiocyanate and 5 µl PI for 15 min at 37˚C in darkness. The apoptotic cells were subsequently analyzed by fluorescence-activated cell sorting (FACSCalibur; BD Biosciences) using Cell Quest Research 3.3 Software (BD Biosciences).
Immunocytochemistry staining. This procedure has been described previously (15) . Briefly, following treatment with 25 µl/ml Delisheng, the Hep3B cells were washed with PBS and then stained with the primary antibodies (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd. Beijing, China) against VEGF (cat.no., ZA-0509), OPN (cat. no., ZM-0174) and ES (cat. no., TA507124) (dilutions, 1:100) overnight at 4˚C. The next day, the cells were washed with PBS 3 times, followed by incubation with a secondary antibody (Biotinylated goat anti-rabbit IgG; cat. no., bs-0294P; Xiamen Bosen Biotechnology Co.
Ltd., Xiamen, China) diluted to 1:500 for 20 min at 37˚C, and then immunostained using an avidin-biotin complex (ABC) protocol (ABC Staining Kits; Xiamen Bosen Biotechnology Co., Ltd. Xiamen, China) for 30 min, according to the protocol of the manufacturer. The color reaction was visualized through a light microscope (Olympus BH-12, Tokyo, Japan) at magnification, x400 using 3,3'-diaminobenzidinefor 5 min. The nuclei were counterstained with hematoxylin (10 mg/ml) solution (Beyotime Institute of Biotechnology, Shanghai, China) at 37˚C for 10 sec.
Evaluation of immunocytochemistry staining. The immunoreactivity was evaluated according to the cell staining degree and percentage rate of the positive cell. Staining intensity was graded as follows: 0, no staining; 1, weak; 2, moderate; and 3, strong. The percentage of positively stained cells was scored as follows: 0, ≤5%; 1, 5-25%; 2, 26-50%; and 3, >50%. The score of staining intensity and percentage score of positive cells were multiplied. In these groups, tumors with 0-2 scores were noted as negative, while 3-9 scores were designated as positive. The immunocytochemical results were quantitatively analyzed using LeicaQ550cw imaging analysis system (Leica Microsystems GmbH, Wetzlar, Germany).
Western blotting. Following treatment with 25 µl/ml Delisheng, the Hep3B cells were harvested in ice-cold PBS and lysed with Table I . Delisheng inhibits the proliferation of Hep3B and HL-7702 cell lines. radioimmunoprecipitation cell lysis buffer containing protease and phosphatase inhibitors (Xi'an Wolsen Biotechnology Co. Ltd., Xi'an, China). Protein concentrations in the cell extracts were determined using the BCA Protein Assay reagents (Pierce; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Each protein sample (30 µg) was subject to 15% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Merck KGaA, Darmstadt, Germany), blocked with 8% non-fat milk for 2 h at RT. The membranes were labeled with primary antibodies overnight at 4˚C. Subsequently, blots were probed with horseradish peroxidase-conjugated secondary anti-rabbit IgG antibodies (1:5,000; cat. no., sc-2004; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at RT for 1 h. The primary antibodies VEGF (cat. no., ab46154), OPN (cat. no., ab8448), ES (cat. no., ab64569) at dilutions of 1:1,000 and β-actin (cat. no., ab8227; 1:5,000) were purchased from Abcam (Cambridge, UK). For the quantification of protein levels, films were scanned and analyzed using Labworks 4.0 software (World BioHazTec Corporation, NM, USA).
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Statistical analysis.
All results were presented as the mean ± standard deviation. Statistical analysis was performed by one-way analysis of variance followed by Tukey's post hoc test. Student's t-test and Spearman's rank test using SPSS v.19.0 (IBM Corp., Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Antiproliferative activity of Delisheng on Hep3B and HL-7702 cells.
The cytotoxic effects of Delisheng were measured by MTT assay. Based on Table I and Fig. 1 , exposure of these cells to Delisheng at the indicated concentrations for 24-72 h periods exhibited growth inhibition effects of Hep3B in a time-and dose-dependent manner. Compared to Hep3B cells, HL-7702 cells were less sensitive to the antiproliferative effects of Delisheng (Table I) .
Effects of Delisheng on the cell cycles of Hep3B cells.
To determine the mechanism underlying the antiproliferative activity of Delisheng on Hep3B cells, cell cycles were tested by flow cytometric analysis. As demonstrated in Table II and Fig. 2 , in Hep3B cells treated with 25, 50 and 100 µl/ml Delisheng, G 0 /G 1 cell cycle arrest was observed. In addition, the results indicated the cells exhibited G 0 /G 1 phase arrest in a concentration-dependent manner.
Delisheng induces apoptosis.
To additionally determine the potential mechanism of the anticancer effects of Delisheng, cell apoptosis was measured by flow cytometry. As indicated by Fig. 3 and Table III 
VEGF, OPN and ES are involved in Hep3B cells treated with
Delisheng. Immunocytochemistry analysis demonstrated that the levels of VEGF, OPN and ES expression were observed in the cytoplasm of Hep3B cells. Fig. 4 indicates that Delisheng treatment increased VEGF and OPN and decreased ES protein expression levels (P<0.05). As observed in Fig. 5 and Table IV , western blotting analysis additionally confirmed the results. Furthermore, the Spearman's rank correlation analysis indicated that OPN was positively correlated with VEGF expression (r=0.58, P=0.011). However, ES was negatively correlated with VEGF (r=0.57, P=0.009) and OPN expression (r=0.69, P=0.025).
Discussion
Delisheng has demonstrated antitumor activities for specific types of cancer (17) (18) (19) . Ginsenoside Rg3 (Rg3), one of the bioactive extracts from Delisheng, exerts an antiproliferation effect on prostate cancer cells (20) . For ~80% of patients with prostate cancer, Delisheng treatment alone may alleviate symptom of weakness, improve quality of life and decrease prostate specific antigen (PSA) levels (21) . Our previous studies suggested that Delisheng exhibited cytotoxic activities and triggered time-and concentration-dependent apoptosis in HepG2 cells by activating the mitochondria-mediated and death receptor-mediated apoptotic pathways (11, 17) .
Cell cycle progression serves a pivotal role in maintaining homeostasis in healthy tissues. Numerous anticancer agents arrest the cell cycle and then induce cell death (22) (23) (24) (25) . In the present study, the results demonstrated that the antiproliferative and proapoptotic activities of Delisheng may be attributed to G 0 /G 1 cell cycle arrest. Delisheng induced antiproliferation and apoptosis in Hep3B cells, but exhibited no significant effect on HL-7702 cells. These data suggested that Delisheng may exhibit less toxicity in normal liver cells compared with in HCC cells.
VEGF and OPN may induce tumor angiogenesis, which is crucial for the malignant process of cancer (26) (27) (28) (29) . VEGF exerts multiple functions including endothelial cell mitogenesis and migration, remodeling of the extracellular matrix, increased vascular permeability and maintenance of the survival of novel blood vessel formation (30) . A number of tumors highly express VEGF, which is correlated with tumor invasiveness, vascular density, metastasis/recurrence and unfavorable prognosis (31) (32) (33) . OPN is a phosphorylated acidic glycoprotein which functions in cell attachment, and is also a cytokine that signals through αvβ3-integrin and cluster of differentiation 44. Binding of OPN to these cell surface receptors stimulates cell adhesion, proliferation and migration (34) . Previous studies indicated that the expression of VEGF was associated with OPN expression, and that they may serve as prognostic factors for non-small-cell lung cancer (27) . The data of the present study demonstrated that Delisheng downregulated VEGF and OPN expression in Hep3B cell ina concentration-dependent manner. ES is a proteolytic cleavage product of type XVIII collagen, and interacts with multiple cell-surface molecules (35) . It inhibits endothelial cells proliferation, migration/invasion and increases tumor cells apoptosis (36) . Furthermore, ES suppressed the expression of VEGF, matrix metalloproteinases, fibroblast growth factor and cell adhesion molecule (37, 38) . Certain previous studies revealed that tumor growth was inhibited in transgenic mice overproducing ES (39, 40) . Based on the results of the present study, the upregulation of ES and downregulation of VEGF and OPN may be responsible for the anticancer effect of Delisheng on Hep3B cells.
Taken together, the results of the present study provide novel evidence that Delisheng induces antiproliferation and apoptosis in Hep3B cells, at least in part through downregulating VEGF and OPN and upregulating ES, which may assist in the validation of the clinical application of Delisheng. Additional studies investigating the underlying anticancer mechanisms and for its potential as a novel anticancer therapeutic in HCC are required.
